Shenzhen Cell Valley successfully completed Angel + Pre-A rounds of capital increase and share expan
Recently, our company successfully completed nearly 100 million yuan of Angel + Pre-A rounds of capital increase and stock expansion, which injected strong momentum into the future development of Shenzhen Cell Valley.
This capital increase and stock expansion has received active support and recognition from new and old shareholders and investors, further enhancing the company's capital strength and market competitiveness.
The main purpose of this capital increase and share expansion is to expand the company's business scale and improve the company's profitability and market competitiveness. Through this capital increase and share expansion, the company successfully introduced new investors, further optimized the company's equity structure, and laid a solid foundation for the company's long-term development.
In the recent severe capital winter, especially when the global cell and gene industries are facing adjustments and comprehensive reshuffles, Cell Valley people adhere to the concept of "cells benefit all living beings, genes create the future", keep their feet on the ground, dig deep into the market, and adhere to the " Research and develop new technologies, forge new production, create new business formats, and open up new markets", insisting on building a technology-driven modern enterprise.
Through the unremitting efforts of all employees, Shenzhen Cell Valley has overcome a number of domestic and international technical problems in cell therapy, such as the production and quality control technology of allogeneic NK cells and the success of a new viral vector toxin-producing engineering cell line with completely proprietary intellectual property rights. Develop and use the world's leading retroviral vector stock solution to transduce primary NK cells with a transduction efficiency of more than 90%.
The company's revenue also increased rapidly in the first quarter, and it has carried out multiple clinical research cooperation with top domestic public hospitals including the Cancer Hospital of the Chinese Academy of Medical Sciences, Beijing Children's Hospital, and Sun Yat-sen University Cancer Prevention and Treatment Center.
The success of this capital increase and share expansion not only demonstrates the strong appeal and market potential of Shenzhen Cell Valley, but also reflects the confidence and recognition of shareholders and investors in the company. In the future, Shenzhen Cell Valley will continue to uphold the innovative, pragmatic and prudent business philosophy, continuously promote the company's business expansion and transformation and upgrading, and create more generous returns for shareholders and investors.
This capital increase and stock expansion has received active support and recognition from new and old shareholders and investors, further enhancing the company's capital strength and market competitiveness.
The main purpose of this capital increase and share expansion is to expand the company's business scale and improve the company's profitability and market competitiveness. Through this capital increase and share expansion, the company successfully introduced new investors, further optimized the company's equity structure, and laid a solid foundation for the company's long-term development.
In the recent severe capital winter, especially when the global cell and gene industries are facing adjustments and comprehensive reshuffles, Cell Valley people adhere to the concept of "cells benefit all living beings, genes create the future", keep their feet on the ground, dig deep into the market, and adhere to the " Research and develop new technologies, forge new production, create new business formats, and open up new markets", insisting on building a technology-driven modern enterprise.
Through the unremitting efforts of all employees, Shenzhen Cell Valley has overcome a number of domestic and international technical problems in cell therapy, such as the production and quality control technology of allogeneic NK cells and the success of a new viral vector toxin-producing engineering cell line with completely proprietary intellectual property rights. Develop and use the world's leading retroviral vector stock solution to transduce primary NK cells with a transduction efficiency of more than 90%.
The company's revenue also increased rapidly in the first quarter, and it has carried out multiple clinical research cooperation with top domestic public hospitals including the Cancer Hospital of the Chinese Academy of Medical Sciences, Beijing Children's Hospital, and Sun Yat-sen University Cancer Prevention and Treatment Center.
The success of this capital increase and share expansion not only demonstrates the strong appeal and market potential of Shenzhen Cell Valley, but also reflects the confidence and recognition of shareholders and investors in the company. In the future, Shenzhen Cell Valley will continue to uphold the innovative, pragmatic and prudent business philosophy, continuously promote the company's business expansion and transformation and upgrading, and create more generous returns for shareholders and investors.
We believe that with the support of shareholders and investors,
Shenzhen Cell Valley will surely usher in a more brilliant future!
